Regonix 40 mg contains Regorafenib, an oral multi-kinase inhibitor used in the treatment of advanced and treatment-resistant cancers. It is designed to target multiple pathways involved in tumor growth, angiogenesis, and cancer cell survival. Regonix 40 mg plays an important role in oncology practice by offering a targeted treatment option for patients who have progressed after standard therapies.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

• Active ingredient: Regorafenib 40 mg

• Dosage form: Oral tablet

Therapeutic Class

• Multi-kinase inhibitor

• Targeted antineoplastic agent

Mechanism of Action

Regorafenib inhibits several protein kinases involved in tumor angiogenesis, oncogenesis, and the tumor microenvironment. These include VEGFR 1–3, TIE2, PDGFR, FGFR, KIT, RET, and RAF kinases. By blocking these signaling pathways, Regonix 40 mg reduces tumor blood vessel formation, slows cancer cell proliferation, and limits tumor progression. Its broad kinase inhibition profile makes it effective against tumors that have become resistant to other targeted therapies.

Indications

Regonix 40 mg is indicated for the treatment of:

• Metastatic Colorectal Cancer in patients previously treated with fluoropyrimidine-based chemotherapy, anti-VEGF therapy, and anti-EGFR therapy (if RAS wild type)

• Gastrointestinal Stromal Tumor (GIST) after failure of imatinib and sunitinib

• Hepatocellular Carcinoma (HCC) in patients who have previously received sorafenib

Dosage and Administration

• The usual recommended dose is 160 mg once daily for the first 21 days of each 28-day treatment cycle.

• Regonix 40 mg tablets allow dose flexibility and titration according to patient tolerance.

• Tablets should be taken orally with a low-fat meal at the same time each day.

• Dose modifications or interruptions may be required based on adverse reactions and clinical response.

Benefits and Features

• Broad-spectrum kinase inhibition for advanced cancers

• Oral therapy that supports outpatient treatment

• Useful in patients with disease progression after standard therapies

• Helps delay disease progression and improve progression-free survival

• Enables individualized dosing under oncologist supervision

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions and Warnings

• Liver function should be monitored regularly due to the risk of hepatotoxicity.

• Regonix 40 mg may increase the risk of hypertension, bleeding, and cardiovascular events.

• Hand-foot skin reaction is a common adverse effect and may require dose adjustment.

• Not recommended during pregnancy or breastfeeding unless clearly advised by a physician.

• Patients should inform their healthcare provider about all current medications before starting treatment.

Side Effects

Common side effects include fatigue, diarrhea, decreased appetite, weight loss, hypertension, hand-foot skin reaction, and voice changes. Serious adverse events are uncommon but may require prompt medical intervention.

Storage

• Store below 30°C

• Protect from moisture and light

• Keep out of reach of children

Regonix 40 mg provides an effective targeted treatment option for patients with advanced malignancies who have limited therapeutic alternatives. When used under specialist care, it supports extended disease control and improved clinical outcomes.